Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 22, 2025

Mesenchymal stem cells-like as a prognostic biomarker in patients diagnosed with acute myeloid leukemia

View Full Paper
Ask AI
Bookmark
Share

Authors

TCTamara Castaño-BonillaDLDaniel Láinez‐GonzálezJSJuana Serrano‐López

Discussion

Loading...

Member takes

Overview

Retrospective analysis reveals MSC-like cell levels impact survival in adult AML patients after chemotherapy, suggesting new prognostic factors.

Key Points

  • Higher proportions of MSC-l cells in bone marrow are linked to worse overall survival in AML patients.
  • Patients categorized as MSC-l<sup>HIGH</sup> had a median overall survival of 0.66 years, significantly less than MSC-l<sup>LOW</sup> patients.
  • The study utilized multiparameter flow cytometry to quantify MSC-l cells in 65 adult AML patients after treatment.
  • Findings indicate MSC-l quantification could enhance prognostic assessments in AML, highlighting the need for further research.

Cite This Study

Castaño-Bonilla et al. (2025) studied this question.

synapsesocial.com/papers/689a061be6551bb0af8cd7fbhttps://doi.org/10.21203/rs.3.rs-7035200/v1
View Full Paper
Ask AI
Bookmark
Share